NCT05191940 2026-03-20
LAPC
EBG MedAustron GmbH
Phase NA Recruiting
Clinical Trials
16 trialsNCT07236177 2026-02-05
B-GLUCANCER2
Poitiers University Hospital
Phase EARLY_PHASE1 Recruiting
NCT03435536 2025-11-28
ICAPAC
University Hospital, Toulouse
Phase NA Completed
NCT05975593 2025-11-12
METEOR-CRATR
Washington University School of Medicine
Phase NA Recruiting
NCT06332274 2025-05-13
UMBRELLA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT03956056 2024-07-17
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Washington University School of Medicine
Phase 1 Terminated
NCT04677244 2024-04-09
EUS-CTC
Institut Paoli-Calmettes
Phase NA Recruiting
NCT03978702 2022-01-06
IMMUNOPANC
Institut Paoli-Calmettes
Phase NA Unknown
NCT03787056 2021-07-16
ONCOPRO
Hospices Civils de Lyon
Phase NA Recruiting
NCT04560270 2020-09-23
CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer
Poitiers University Hospital
Phase NA Completed
NCT02887599 2019-01-16
Assessment of the Cytotoxic Immune Status of Pancreatic Cancer Patients and the Severity of the Cancer Using Measurement of Natural Killer Cell Activities
Yonsei University
Phase NA Completed
NCT02500004 2018-08-03
BAT-Cachexia
Maastricht University Medical Center
Phase NA Completed
NCT01392027 2017-11-08
SPORE-PANC
University of Michigan
Phase NA Completed
NCT02241187 2017-09-27
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01434550 2017-02-23
Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Withdrawn
NCT01227018 2014-07-23
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated